THOUSAND OAKS, Calif., Oct. 14 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that results from several Prolia™ (denosumab) studies, as well as analyses of the growing global burden of osteoporosis, will be presented at the 2010 American Society for Bone and Mineral Research (ASBMR) annual meeting in Toronto, Ontario from Oct. 15-19, 2010.
"The continued need to reduce fractures caused by postmenopausal osteoporosis is reinforced by data that will be presented at this year's ASBMR meeting. These data highlight the global economic burden associated with osteoporotic fractures, the challenges with adherence to oral therapies, and the link between adherence and fracture outcomes," said Catherine Stehman-Breen, M.D., vice president of Global Development at Amgen. "Additionally, safety and efficacy results from the Prolia FREEDOM extension study will be available along with two new analyses of FREEDOM that evaluated the effect of Prolia on bone strength."
ASBMR abstracts are available and can be viewed online at www.asbmr.org. Identified below are selected abstracts of interest on Amgen research. Prolia Clinical Data
Hip QCT Results From the FREEDOM Trial: Evidence for Positive BMD/BMC Changes in Integral, Trabecular, and Cortical Bone With DenosumabLead Author: Prof. Harry K. Genant, University of California, San FranciscoAbstract No. FR0410 Oral Plenary/Poster Presentation(Friday, Oct. 15, 5:10 p.m.-5:15 p.m. ET)
Four years of denosumab exposure in women with PMO: Results from the first year extension of the FREEDOM TrialLead Author: Socrates Papapoulos, Leiden University Medical Center, The NetherlandsAbstract No. 1025 Oral Presentation(Saturday, Oct. 16, 10:00 a.m.-10:15 a.m. ET)
Copyright©2010 PR Newswire.
All rights reserved